Benign prostate phyllodes tumor

Summary

Benign prostate phyllodes tumor (MONDO:0002451) is a cancer. A subtype of benign urinary system neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign prostate phyllodes tumor
Mondo ID	MONDO:0002451
DOID	DOID:2885
NCIT	C5532
UMLS	C1332535
MedGen	272364
GARD	0023140
Is cancer (heuristic)	yes

Also known as: benign phyllodes neoplasm of prostate · benign phyllodes neoplasm of the prostate · benign phyllodes tumor of prostate · benign phyllodes tumor of the prostate · benign phyllodes tumour of prostate · benign phyllodes tumour of the prostate · benign prostate phyllodes neoplasm · benign prostate phyllodes tumor · phyllodes neoplasm of the prostate · prostate phyllodes tumor · prostate phyllodes tumor, benign · prostate phyllodes tumour

Disease family

This is a subtype of benign urinary system neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign urinary system neoplasm › benign prostate phyllodes tumor

Related subtypes (5): bladder benign neoplasm, ureter benign neoplasm, kidney benign neoplasm, urothelial papilloma, benign urethral neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.